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Hypertrophic Ca~i~~yQ 
Geneml Considerations 
Hypertrophic cardiomyopathy, although a relatively un- 
common cardiac malformation (-0.1% to 0.2% of the general 
population) (I), is of great importance bccausc it is probably 
the most common cause of uncxpccted sudden cardiac death in 
young people, including competitive athletes (2-12). Indeed, 
sudden death in hypertrophic cardiomyopathy usually occurs 
in the absence of previous symptoms (2-7,10-12). 
Hypertrophic cardiomyopathy is a primary cardiac disease 
in which the most consistent diagnostic feature demonstrated 
by echocardiography is an asymmetrically hypertrophied and 
nondilated left ventricle in the absence of another cardiac or 
systemic disease associated with left ventricular hypertrophy 
(13). The clinical and morphologic expression and natural 
history is recognized to be particularly diverse and hetero- 
geneous (14-21). The familial form of the disease (22) is 
genetically heterogeneous and has been attributed to several 
genetic defects invoking contractile proteins trcponin T and 
alpha-trcpomyosin and a number of missense mutations of the 
beta-myosin heavy-chain gene (23-26). 
Hypertrophic cardiomyopathy is generally regarded to be 
present when the maximal diastolic left ventricular wall thickness, 
as defined by echocardiography, is 215 mm in an adult (or the 
equivalent, relative to body surface area, in children). However, it 
is also recognized that some a&ted patients with hypertrophic 
caLrdiowpathy have wall thicknesses Cl5 mm (21,22), whereas 
a subgroup of highly trained male athletes without cardiovascular 
disease (i.e., athlete’s heart with physiologic hypertrophy) may 
show wall thicknesses that exceed normal limits (i.e., >l2 mm, 
ranging up to I6 mm) (27). Therefore, left ventricular wall 
thicknesses of I3 to 14 mm may place an individual athlete in an 
inconclusive diagnostic “gray zone” (28). Such a circumstance 
may not easily permit a definitive distinction of hypertrophic 
cardiomyopathy from the physiologic “athlete’s heart,” in which 
left ventricular hypertrcphy is not truly pathologic (28). In such 
instances, additional data, including identification of other echo- 
cardiographic or clinical features most consistent with either 
hypertrophic cardiomyopathy or “athlete’s heart” (29,30), should 
be sought to resolve this sometimes difficult differential diagnosis. 
It should be emphasized thiit there is also considerable risk 
to the well-being of the athlete associated with the cverdiag- 
ncsis of hypertrophic cardiomyopathy in borderline cases 
because this diagnosis may be based solely on the echocardic- 
graphic assessment of left ventricular wall thickness and often 
in only a single segment of the ventricle. Therefore, the reccm- 
mendations of this Task I&c are predicated on the presumption 
that the clinical diagnosis of hypertrcphic cardiomyopathy in a 
given athlete has been judged to be highly probable or definite. 
In hypertrcphic cardiomyopathy, the pattern and extent of left 
ventricular hypertrophy is diverse, but a greater magnitude and 
extent of wall thickening appear to convey less favorable clinical 
consequences (9,31,32). We also recognize that the phenctypic 
expression of hypertrophic cardiomyopathy (i.e., unexplained left 
ventricular wall thickening) may be incompletely expressed in 
young patients who are in the age range of many competitive 
athletes (i.e., ~18 years old), and in some instances full morpho- 
logic manifestation of the disease may not be clearly evident until 
young adulthood (33). 
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demonstration of unexplained l ft ventricular ~y~ertro~hy by 
ho-dimensional ecb~~rd~ogra~by represents the sine qua non of 
clinical diagnosis (13,14,16). Recent identification f gene or 
disease loci responsible forh~ertroph~c cardiomyopathy raises 
the possibility of diagnosis, by virtue of genetic testing for 
the known molecular bnormalities (23-26). Such testing may 
achieve a practical pplication in those individuals for whom a 
precise clinical diagnosis of ~~ypertropl~i~ card o 
certain for a variety of reasons, ~~cl~~i~g yo 
athletes) in whom there is not yet a definit 
identified by e~l~~ardio~m~hy (26). 
The present recommendations are 
ubhsbed data and clinical experiences 
but also on a “common sense” approach to t 
practice. The relative risk for su den death by virtue of 
participating in competitive athlet s with hypertrophic car- 
diomyopathy is largely unknown, and some athletes may 
tolerate extreme athletic life-styles with extraordinary levels of 
systematic raining without incurring either sudden cardiac 
death or disease progression (34). At present, insufficient data 
are available that support particular invasive or noninvasive 
approaches fordefinitively stratifying risk for sudden death in 
iudividual youthful patients with hypertrophic cardiomyopathy 
(35). Indeed, the magnitude of risk for sudden death is 
undoubtedly determined by muhiple factors, including the 
nature and intensity of the at l&c training and competitive 
situations, as well as particular features of the individual 
patient’s cardiomyopathic disease tate (10). The latter include 
potential trigger mechanisms (paroxysmal atria1 fibrillation, 
ventricular rhythmia, acceler or impaired atrioventricu- 
lar conduction and myocardial mia) (3,6,7,10,35) in addi- 
tion to the extent of myocardia ray (7), which presumably 
represents the substrate for electrical instability (10). 
We recognize that all patients orathletes with hypertrophic 
cardiomyopathy areundoubtedly not at the same risk for 
sudden cardiac death (3,4,10,34-38). However, the differenti- 
ation of subgroups ofyoung patients with differing risks has 
proved challenging and, unfortunately, at present remains 
unresolved. Although electrophysiologic testing with pro- 
grammed lectrical stimulation has provided some measure of
predictability with regard to outcome inhigh risk patients with 
coronary artery disease (39), it is not necessarily valid to make 
inferences from those data to patients with a diverse and 
heterogeneous disease such as hypertrophic ardiomyopathy 
(6,7,14,15,40), or in particular to the highly selected subset of 
trained athletes with this disease who have experienced x- 
traordinary life-styles without previous cardiovascular symp- 
toms or evidence ofventricular rhythmia (34). Indeed, in a 
disease such as hypertrophic cardiomyopathy in which there is 
a propensity for potentially lethal arrhythmias insome individ- 
uals, the stress of athletic training and competition as well as 
associated alterations in blood volume, ration and eiectro- 
es that may occur make a extrapolation from assessment 
risk in nonathletes wit ertrophic ardiomyopathy di- 
rectiy to highly trained co ve athletes with this condition 
very tenuous. 
~~ectrophys~olog~~ testingwith programmed electrical sum- 
ulation has been applied in highly selected populations ofhigh 
risk patients with hypertrophic cardiomyopathy (who were not 
athletes) with symptoms of impaired consciousness or vent+ 
ular arrbytbmias, or both, in an effort o identify subgroups at 
increased risk for sudden cardiac death on the basis of 
inducibility of ventricular arrhythmias (polymorphic or mono- 
morphic ventricular tachycardia or ventricular fibrillation) 
(41-47). However, in patients with hypertrophic cardiomyo- 
pathy, the predictive accuracy ofinducible, sustained ventric- 
ular arr~~ythmias for sudden death is low and not predictive of 
clinical outcome; aggressive stimulation protocols induce sus- 
tained ventricular rhythmias in the majority of high risk 
patients as well as in many patients who appear to be at low 
risk (41,45,46,48). Conversely, stimulation protocols judged to 
be less aggressive generate a low inducibility rate even in 
patients who are known to be at increased risk (43). 
because of its relatively low predictive accuracy, pr 
electrical stimulation does not at present permit 
clinical decisions to be made in individual athletes with hyper- 
trophic cardiomyopathy regarding prediction of outcome or 
design of treatment strategy (4E). 
The fact hat we are not able at present to stratify risk for 
athletes with hypertrophic cardiomyopathy is reflected in the 
present recommendations for athletic eligibility that are both 
conservative and similar for most athletes with hypertrophic 
cardiomyopathy, Current investigative efforts are directed at 
improving risk stratification assessment in hypertrophic cardiom- 
yopathy. We anticipate that future investigative work in molecular 
genetics and electrophysiology and in the evaluation ofvascular 
responses will more accurately define variables of hemodynamic 
and electrical instability and permit more reliable identification f 
those athletes with this disease who are at particular risk for 
sudden cardiac death. 
ecommendations 
1. Athletes with the unequivocal diagnosis of hypertrophic 
cardiomyopathy should not participate in most competitive 
sports, with the possible xception of those of low intensity 
(class IA [see Table 1 in Classification of Sports]). This rec- 
ommendation includes those athletes with or without symp 
toms or left ventricular outflow obstruction. 
2. In recognition ofthe observation that the risk for sudden 
cardiac death may be reduced in older patients with hypertro- 
phic cardiomyopathy (3,4,10,35), we alternatively suggest that 
individual judgment inassessing eligibility may be utilized in 
selected older athletes (>30 years old) for whom each of the 
following clinical features (judged or established to be unfa- 
vorable or potential risk factors for sudden death) are U~NW 
a) ventrh&r tachycardia (sustained ornonsustained) on ambu- 
latory ECG (37,38); b)family history of sudden death due to 
hypertrophic cardiomyopathy, particularly if Occurring at <40 
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years of age (2,6,7,15,25); c) history of syncope or other 
clinically relevant episodes ofimpaired consciousness (36,49); 
d) severe hemodynamic abnormahties, including a dynamic left 
ventricular outflow tract gradient (~50 mm Hg) (50-52); e) 
exelcise-induced hypotension (53); f) moderate osevere mitral 
rogurgiration, enlarged left atrium (250 mm) or paroxysmal atrial 
fibrillation (54); and g) evidence of abnormal myocardial 
perfupion. 
These recommendations arenot altered if medical or 
surgical treatment is undertaken in an individual thlete (6J). 
With the advent of the preclinical genetic diagnosis of hyper- 
tmphic -thy (26), a small number ofyouthful family 
members have been identified asaffected onthe basis of a DNA 
is in the absence of typical morphologic features oftheir 
ihcance ofsuch findings i  uncertain, and 
at present there is no available evidence to preclude such subjects 
from competitive athletics in the absence of cardiac symptoms or 
a family history of sudden cardiac death. 
Mitral valve prolapse isof particular concern to physicians 
evaluating large numbers ofathletes for competition because 
of its relatively high prevalence in the general population 
(estimated to be -5%) (55). 
Mitral valve prolapse isa generally benign disorder, char- 
acterized bysystolic protrusion ofthe mitral valve leaflets into 
the left atrium (as demonstrated by echocardiographic and
angiographic studies) (56,57). A midsystoiic (nonejection) 
click, with or without alate systolic murmur, isthe auscultatory 
hallmark ofthis condition (55-M). 
In some patients, mitral valve prolapse isassociated with 
palpitations, dizziness, an abnormal 12.lead electroeardio.gram 
and supmventricular or ventricular rhythmias (55-60); syn- 
icnts is often due to orthostetic hypotension 
ow blood volume (61). Mitral valve prolapse 
cause of chronic mitral regurgitation (some- 
times ass&ated with bacterial endocarditis) necessitating op-
erative valve repair or replacement, and, on occasion, of 
cerebrovascular accident or sudden cardiac death (55,62-75). 
It has been proposed that it is the morphologic form of mitral 
valve prolapse inwhich a structural abnormality of the mitral 
valve is clearly evident (i.e., leallet thickening and elongation a d 
myxomatous degeneration) associated with substautial systolic 
pmtmsion of the valve into the left atrium that conveys the 
greatest risk for unfavorable sequelae (63). Relatively mild sys- 
the leafiets (patticuhuly when limited to the 
phie apical four-chamber vi w) and associated with 
normal mitral valve is a nonspecific nding and 
represents a normal variant or benign form within the 
broad clinical spectrum of this diverse condition (63). 
Available clinical evidence supports a generally favorable 
pqnasis for patients within the disease spectrum of mitral 
vaive prolapse. Although sudden cardiac death has been 
reported in patients with mitral valve prolapse (5,X&55,65-70,73), 
such occurrences appear tobe rare; furthermore, athletes who die 
suddenly rarely have myxomatous mitral valve abnormalities at 
autopsy (5565-67). To date, -12 patients documented to have 
mitral valve prolapse are described in published reports to have 
died suddenly during exercise (5,12,60,67-69,73), and 5 of these 
were trained competitive athletes at the time of their death 
(5,12,69,70,73). Coexistence of mitral valve prohapse and 
trophic ardiomyopathy in the same patient does not a 
convey a particularly unfavorable prognosis (75). 
ecommendetiom 
1. Athletes with mitral valve prolapse (having a structurally 
abnormal valve rn~~ifest~~ by teatlet t~i~ken~~g and e~ongat~~~l~ 
and without any of the following criteria can engage in all 
competitive sports: a) history of syncope, documented to be 
arrhythmogenic i  origin; b) family history of sudden death 
associated with mitral valve pr~~~a~; c) repctitivc forms of 
sustained and nonsustained supraventricular tachyarrhythmias or 
complex ventricular rrhythmias, particularly if exa rated by 
exercise (see also Task Force 6); d) moderate to marked mitral 
regurgitation; e) prior embohc event. 
2. Athletes with mitral valve prolapse and any of the 
aforementioned criteria can participate in low intensity com- 
petitive sports only (class IA). 
Recommendations related to the hemodynamic burden of 
mitral regwrgitation in athletes with mitral valve prolapse 
appear in Task Force 2. 
Gtmral Considerations 
iCis 
Myocarditis (usually of viral etiology due to Coxsackie R) 
has been regarded as an uncommon cause of sudden death in 
young competitive athletes (5.12); in some instances, viral 
tnyocarditis may culminate in dilated cardiomyopathy with 
chronic ardiac dysfunction, presumably as a consequence of 
viral-mediated immunologic cardiac damage (76). However, 
the frequency with which myocarditis occurs in young athletes 
has been a source of controversy due, in large measure, tothe 
often substantial uncertainty regarding the precise criteria for 
the clinical or even histologic diagnosis of the disease. 
Myocarditis suspected clinically by virtue of fatigue, 
exertional dyspnea, syncope, palpitations, arrhythmias or acute 
congestive heart failure in the presence of left ventricular 
dilation and associated with evidence ofventricular dysfunc- 
tion (usually segmental wall motion abnormalities) or ST-T 
changes on the ECG. Morphologic criteria have also been 
proposed (e.g., the consensus Dallas criteria) (77), which 
represent useful definitions for more consistent and rigorous 
pathologic diagnosis of myocarditis. These emphasize that 
myocarditis is a process characterized by an inflammatory 
infiltration ofthe myocardium with necrosis ordegeneration of 
adjacent myocytes, or both, not typical of the ischemic damage 
characteristically associated with eoronaty artery disease. 
The present recommendations underscore th  heterogeneous 
nature of myocarditis and the fact hat he disease process evolves 
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~~icu~a~~y true if, in addition to those cases in which pathologic 
examination describes a docum ~~~fl~~~~rn~~to~ cell infiltrate 
(12,7&79), other casts are inc that are consistent witb 
healed tny(~i~rditis by virtue of foci of replacement fibrosis in the 
illM2lCe of ~XMllll~ill atherosclerotic coronary artery narrowing 
(:md iiSSOCiWXl with 11Wllill kilrt weight and cavity size) (80). 
t has been proposed that sudden death occu~ri~~g in heated 
(ZIS well ;ls active) myocarditis is due to a rhythm disturbance 
developing in the setting of an unstable lcfl VClltriCUliw elec- 
IriCill SubStrate. Although niyocardilis is often infectious in 
origin, it is worth noting that histologic evidence of the acute 
illld healed ~IlilSCS lllay idSO IW it CO~lSC~UCllCO of long-term 
cocaine IIW (8145). There is a body of largely anecdotal data 
suggesting that cocail~c abuse is H growing and prevalent 
problem among segments of the general and athletic popula- 
tion, with the potential to lead to complications such as 
myocardial damage and dysfunction. 
If clinical judgment suggests the plcsencc of myocarditis in 
an athlete, the possibility of performing an cndomyocardial 
biopsy for the purpose of confirming that diagnosis should bc 
considered. We recognize that an endomyocardial biopsy 
positive for myocarditis may clarify an otherwise ambiguous 
clinical profile. Conversely, biopsy is not required when strong 
clinical evidence of the disease is present. 
I. Athletes judged as probably having myocarditis should be 
withdrawn from all competitive sports and undergo a prudent 
convalescent period of -6 months after the onset of clinical man- 
ifestations. Before the athlete may return to competitive athletic 
training, an evaluation of cardiac status should be undertaken, 
including assessment of ventricular function at rest and with 
exercise (with radionuclidc angiography or echocardiograpby), 
2. An athlete should bc allowed to return to competition 
when ventricular function and also cardiac dimensions have 
returned to normal, and clinically relevant arrhythmias (repetitive 
forms of ventricular ectopic activity or sustained supraventricular 
tachycardia) are absent on ambulatory monitorins. 
3. Sufficient clinical data are not available to justify a strong 
recommendation to perform endomyocardial biopsy as a pre- 
condition for return to athletic competition after the proposed 
6-month period of deconditioning. The role of invasive elec- 
trophysiologic testing in assessing the eligibility of athletes with 
myocarditis remains to be defined. 
ekwditis 
Athletes with pericarditis, regardless of etiology, should not 
participate in competitive sports during the acute episode. Such 
athletes can return to n there is no longer 
physical examination, 
nd an ambulator and 
pericarditis associated 
with evidence of significant myocardial involvement, recommen- 
dations should be based predominantly on the course of the 
myocarditis. Athletes with chronic pericardial disease that results 
in constriction should not engage in any competitive sports. 
A number of other uncommon diseases of the right or left 
ventricle deserve consideration here as potential causes of sudden 
death in athletes. These include idiopathic dilated cardiomyopa- 
thy (76); primary restrictive cardiomyopathies, such as endomyo- 
cardial fibrosis with or without eosinophilia (86), and systemic 
diseases with cardiac involvement, such as sarcoidosis (87). 
Arrhytbmogenic right ventricular dysplasia has been cited 
as a frequent cause of sudden death in young people and 
atblctcs in the northeastern (Veneto) region of Italy (88,89), 
altbough it is apparently less common in other geographic re- 
gions, including the United States (12). The definitive diagnosis of 
this condition is based on demonstration of fibro-fat 
ment of the right ventricular myocardium (88-90). 
during life, although challenging (90), relies on clinical manifes- 
tations of the disease, including ventricular arrhythmias, depolar- 
ization and repolarization alterations on the KG, right ventric- 
ular dilation and hypokinesia and familial occurrence of the 
disease (with or without sudden death) (88-90). 
Few data are available with regard to the relative risks of 
athletic training and competition in athletes with the afore- 
mentioned myocardial diseases. Therefore, until more infor- 
mation is available in this regard, athletes with these diseases 
are advised not to participate in any competitive sports. 
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Systemic hypertension isthe most common cardiovascular 
condition observed in competitive athletes. The diagnosis of 
hypertension is based on the presence of blood pressure 
persistently at or above certain levels as measured by routine 
sphygmomanometry on at least hree separate occasions (Ta- 
ble 1). In determining the level of competitive athletic activity 
that a hypertensive p rson may assume, it is also important to 
ascertain the degree of hypertension-related target organ 
damage (1). Although hypertension is associated with an 
increased risk for sudden death and complex ventricular 
arrhythmias (2), this disease has not yet been incriminated as a 
cause of sudden cardiac death in young competitive athletes 
